Revolution Medicines RVMD
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Revolution Medicines (RVMD) Business Model and Operations Summary
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Key Insights
Revolution Medicines (RVMD) Core Market Data and Business Metrics
Latest Closing Price
$33.62Market Cap
$6.19 BillionPrice-Earnings Ratio
-9.39Total Outstanding Shares
185.91 Million SharesTotal Employees
534Dividend
No dividendIPO Date
February 13, 2020SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
700 Saginaw Dr, Redwood City, CA, 94063
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-554.39 Million |
| Net Cash Flow From Investing Activities | $-554.39 Million |
| Net Cash Flow From Financing Activities | $959.41 Million |
| Net Cash Flow, Continuing | $-152.42 Million |
| Net Cash Flow From Operating Activities | $-557.44 Million |
| Net Cash Flow From Financing Activities, Continuing | $959.41 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Other Operating Expenses | $97.30 Million |
| Basic Earnings Per Share | $-3.58 |
| Income/Loss From Continuing Operations Before Tax | $-600.85 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Research and Development | $592.23 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-599.32 Million |
| Other Comprehensive Income/Loss | $777,000 |
| Comprehensive Income/Loss Attributable To Parent | $-599.32 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Intangible Assets | $56.67 Million |
| Other Current Liabilities | $109.49 Million |
| Equity | $2.27 Billion |
| Assets | $2.56 Billion |
| Accounts Payable | $54.43 Million |
| Noncurrent Liabilities | $129.18 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||